Candidiasis - Pipeline Review, H2 2018

Date: August 14, 2018
Pages: 162
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C1A9F76F89FEN
Leaflet:

Download PDF Leaflet

Candidiasis - Pipeline Review, H2 2018
Candidiasis - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H2 2018, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 8, 3, 27, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Candidiasis - Overview
Candidiasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Candidiasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Candidiasis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals Inc
APEIRON Biologics AG
Bakker Medical Srl
Beta Pharma Inc
Bionex Pharmaceuticals LLC
Biosergen AS
Cellix Bio Pvt Ltd
Cidara Therapeutics Inc
General Biologicals Corp
Grupo Ferrer Internacional SA
Helix BioMedix Inc
iCo Therapeutics Inc
Matinas BioPharma Holdings Inc
Nanomerics Ltd
Nosopharm SAS
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Onxeo SA
Pulmocide Ltd
Scynexis Inc
Sealife PHARMA GMBH
Viamet Pharmaceuticals Inc
Visterra Inc
Wellstat Vaccines LLC
Candidiasis - Drug Profiles
(clotrimazole + diclofenac sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
61894700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Target Ece1 for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-001A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arasertaconazole nitrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-5923 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSG-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
candidiasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-159 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-1593 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSA-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Oral Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Forazoline A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrexafungerp - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iCo-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iCo-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iCo-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JSM-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KSL-W - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miconazole nitrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mutanobactin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYC-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDV-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDV-3A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOSO-F2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-339 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obliquumol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Occidiofungin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-113Du - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-113Tri - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PC-1244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide for Candidiasis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rezafungin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Systemic Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Ece1 for Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-FNG - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voriconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Candidiasis - Dormant Projects
Candidiasis - Discontinued Products
Candidiasis - Product Development Milestones
Featured News & Press Releases
Jul 18, 2018: The World Health Organization Recognizes New Antifungal Class by Granting 'ibrexafungerp' to SCYNEXIS as the International Non-Proprietary Name for SCY-078
Jul 10, 2018: SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
Jun 27, 2018: SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
Jun 14, 2018: SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018
Jun 11, 2018: SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
Jun 06, 2018: Matinas BioPharma to Present Preclinical Data of Candidiasis Drug Candidate MAT2203 at ASM Microbe 2018
Jun 06, 2018: SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
May 24, 2018: SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
May 23, 2018: Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara s Rezafungin for the Treatment of Invasive Fungal Infections
May 01, 2018: SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Apr 30, 2018: Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Candidiasis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Universities/Institutes, H2 2018
Products under Development by Universities/Institutes, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2018
Candidiasis - Pipeline by APEIRON Biologics AG, H2 2018
Candidiasis - Pipeline by Bakker Medical Srl, H2 2018
Candidiasis - Pipeline by Beta Pharma Inc, H2 2018
Candidiasis - Pipeline by Bionex Pharmaceuticals LLC, H2 2018
Candidiasis - Pipeline by Biosergen AS, H2 2018
Candidiasis - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Candidiasis - Pipeline by Cidara Therapeutics Inc, H2 2018
Candidiasis - Pipeline by General Biologicals Corp, H2 2018
Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H2 2018
Candidiasis - Pipeline by Helix BioMedix Inc, H2 2018
Candidiasis - Pipeline by iCo Therapeutics Inc, H2 2018
Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H2 2018
Candidiasis - Pipeline by Nanomerics Ltd, H2 2018
Candidiasis - Pipeline by Nosopharm SAS, H2 2018
Candidiasis - Pipeline by Novabiotics Ltd, H2 2018
Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H2 2018
Candidiasis - Pipeline by Novartis AG, H2 2018
Candidiasis - Pipeline by Onxeo SA, H2 2018
Candidiasis - Pipeline by Pulmocide Ltd, H2 2018
Candidiasis - Pipeline by Scynexis Inc, H2 2018
Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2018
Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H2 2018
Candidiasis - Pipeline by Visterra Inc, H2 2018
Candidiasis - Pipeline by Wellstat Vaccines LLC, H2 2018
Candidiasis - Dormant Projects, H2 2018
Candidiasis - Dormant Projects, H2 2018 (Contd.1), H2 2018
Candidiasis - Dormant Projects, H2 2018 (Contd.2), H2 2018
Candidiasis - Dormant Projects, H2 2018 (Contd.3), H2 2018
Candidiasis - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Candidiasis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

COMPANIES MENTIONED

Amplyx Pharmaceuticals Inc
APEIRON Biologics AG
Bakker Medical Srl
Beta Pharma Inc
Bionex Pharmaceuticals LLC
Biosergen AS
Cellix Bio Pvt Ltd
Cidara Therapeutics Inc
General Biologicals Corp
Grupo Ferrer Internacional SA
Helix BioMedix Inc
iCo Therapeutics Inc
Matinas BioPharma Holdings Inc
Nanomerics Ltd
Nosopharm SAS
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Onxeo SA
Pulmocide Ltd
Scynexis Inc
Sealife PHARMA GMBH
Viamet Pharmaceuticals Inc
Visterra Inc
Wellstat Vaccines LLC
Skip to top


Vulvovaginal Candidiasis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 63 pages

Ask Your Question

Candidiasis - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: